Nirupama Kandula

Nirupama Kandula

Auto-generated profile, based on publicly available information

Nirupama Kandula

Department of Microbiology

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 October 2022 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
NKNirupama Kandula
Nirupama Kandula
Saurabh KumarSaurabh Kumar
Saurabh Kumar
VMvenkata kiran kumar Mandlem
venkata kiran kumar Mandlem
ASAneela Siddabathuni
Aneela Siddabathuni
SSSanjay Singh
Sanjay Singh
RKRamoji Kosuru
Ramoji Kosuru
Recent studies indicate cell death is the hallmark of cardiac pathology in myocardial infarction and diabetes. The AMP‐activated protein kinase (AMPK) signalling pathway is considered a putative salvaging phenomenon, plays a decisive role in almost all cellular, metabolic, and survival functions, and therefore entails precise regulation of its activity. AMPK regulates various programmed cell death depending on the stimuli and context, including autophagy, apoptosis, necroptosis, and ferroptosis. There is substantial evidence suggesting that AMPK is down‐regulated in cardiac tissues of animals and humans with type 2 diabetes or metabolic syndrome compared to non‐diabetic control and that stimulation of AMPK (physiological or pharmacological) can ameliorate diabetes‐associated cardiovascular complications, such as myocardial ischemia‐reperfusion injury. Furthermore, AMPK is an exciting therapeutic target for developing novel drug candidates to treat cell death in diabetes‐associated myocardial ischemia‐reperfusion injury. Therefore, in this review, we summarized how AMPK regulates autophagic, apoptotic, necroptotic, and ferroptosis pathways in the context of myocardial ischemia‐reperfusion injury in the presence and absence of diabetes.